Abstract: The invention comprises methods for identifying mutations within the 3?UTR of genes that lead to increased risk or probability of developing cancer.

Abstract: The invention provides methods for identifying mutations, such as single nucleotide polymorphisms (SNPs), within breast and ovarian cancer associated genes that modify the binding efficacy of microRNAs (miRNAs). In a preferred embodiment, methods of the invention identify a SNP that decreases expression of the BRCA1 gene by increasing or decreasing the binding efficacy of at least one miRNA. Alteration of miRNA binding to BRCA1 by the introduction of SNPs within miRNA binding sites modulates or decreases BRCA1 expression, ultimately leading to the unregulated cell proliferation of a breast or ovarian cancer cells.

Abstract: The invention comprises methods for identifying mutations within the 3?UTR of genes that lead to increased risk or probability of developing cancer.

Abstract: The disclosure provides methods for identifying a subject at risk of developing cancer, predicting the onset of cancer, and predicting a subject's response to chemotherapy/treatment by determining the presence or absence of a SNP in the KRAS oncogene, known as the KRAS variant.

Abstract: The invention provides methods for predicting an increased risk or probability of developing endometriosis in a patient based upon the patient's KRAS variant status.

Abstract: The disclosure provides methods for identifying a subject at risk of developing cancer, predicting the onset of cancer, and predicting a subject's response to chemotherapy/treatment by determining the presence or absence of a SNP in the KRAS oncogene, known as the KRAS variant.

Abstract: The invention provides miRNA signatures and methods of making and using thereof. MiRNA signatures determine the responsiveness of HER2 expressing breast tumors to anti-HER2 treatment, such as the targeted drug therapy trastuzumab.

Abstract: The invention provides a papillary serous miRNA signature and methods for determining the identity, origin, and stage, of concurrent endometrial and ovarian papillary serous tumors. Exemplary origins of concurrent endometrial and ovarian tumors include, but are not limited to, the uterus, ovary, fallopian tubes, and peritoneum.

Abstract: The invention comprises methods for identifying mutations within the 3? UTRs of genes that lead to increased risk or probability of developing cancer.

Abstract: The invention provides methods for identifying mutations, such as single nucleotide polymorphisms (SNPs), within breast and ovarian cancer associated genes that modify the binding efficacy of microRNAs (miRNAs). In a preferred embodiment, methods of the invention identify a SNP that decreases expression of the BRCA1 gene by increasing or decreasing the binding efficacy of at least one miRNA. Alteration of miRNA binding to BRCA1 by the introduction of SNPs within miRNA binding sites modulates or decreases BRCA1 expression, ultimately leading to the unregulated cell proliferation of a breast or ovarian cancer cells.

Abstract: The invention comprises methods for identifying mutations within the 3? UTRs of genes that lead to increased risk or probability of developing cancer.

Abstract: The invention provides methods for predicting an increased risk or probability of developing breast or ovarian cancer in a patient based upon the patient's KRAS-Variant and BRCA status.

Abstract: The invention comprises compositions and methods for modifying gene expression. Modified oligos of the invention restore the lost function of let-7 wild type miRNA molecules that are prevented from silencing target genes by mutations occurring within their binding sites. Administration of a particular modified oligo (SEQ ID NO: 22) leads to increased cell death in cancer cells carrying the LCS6 SNP.

Abstract: The invention comprises methods for identifying mutations within the 3? UTRs of genes that lead to increased risk or probability of developing cancer.

Abstract: The invention comprises methods for identifying mutations within the 3? UTRs of genes that lead to increased risk or probability of developing cancer.